Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease

• Status: Terminated
• Trial end date: 2008-08-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Studying samples of blood from patients with cancer, hepatitis C, or Crohn disease in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer and other diseases.

PURPOSE: This laboratory study is looking at the effect of biological therapy on biomarkers in patients with untreated hepatitis C, metastatic melanoma, or Crohn disease.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vanderbilt-Ingram Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Infliximab; Interferon-alpha; Interferons; Ribavirin; Tremelimumab

Criteria

Inclusion Criteria:

DISEASE CHARACTERISTICS:

• Diagnosis of 1 of the following:

• Acute or chronic hepatitis C

• Receiving pegylated interferon alfa and ribavirin

• Metastatic melanoma

• Receiving ticilimumab

• Crohn disease

• Received prior infliximab

Exclusion Criteria:

• Not specified

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics